alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › mechanistic

mechanistic

3 studies tagged mechanistic, dated 2022-01-18 to 2026-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development 2026-01-01
  2. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective 2023-01-01
  3. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise 2022-01-18

Studies

3 studies carry this tag.

Date range

2022 to 2026

Top journals

  • Current neuropharmacology 1
  • Journal of Alzheimer's disease : JAD 1
  • The FEBS journal 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Current neuropharmacology 2026-01-01 Treatments

    We identify a risk hierarchy for ARIA-H among anti-Aβ mAbs and link specific mAb biophysical properties-Aβ binding type, affinity for soluble oligomers, epitope specificity, Fc structure, and plaque clearance dynamics-directly to ARIA-H pathogenesis.

  2. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01 Treatments

    In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer's disease (AD)-associated cognitive decline.

  3. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The FEBS journal 2022-01-18 Genetics

    Alzheimer's disease (AD) is an age-associated neurodegenerative disorder with multifactorial etiology, intersecting genetic and environmental risk factors, and a lack of disease-modifying therapeutics.

All topic tags with their study counts